Omega Therapeutics(OMGA) - 2024 Q2 - Quarterly Results

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress • Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024 • Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expression • Strengthened leadership team with appointment of Kaan Certel, Ph.D., as ...